Swetha Kambalapally
Tanzania
Research Article
A Self Assembling Nanoemulsion of Lovastatin (SANEL) Decreases Cholesterol Accumulation and Apob-100 Secretion Greater than Lovastatin alone a Hepg2 Cell Line
Author(s): Srikanth Kakumanu, Swetha Kambalapally and Robert J. NicolosiSrikanth Kakumanu, Swetha Kambalapally and Robert J. Nicolosi
Elevated circulating low density lipoprotein-cholesterol (LDL-C) levels contribute to the development of
cardiovascular disease (CVD). Lovastatin, one of the earliest statins which lowers blood LDL-C and as with the more recent statins, has been reported to reduce mortality due to CVD. However, Lovastatin requires higher doses than other newer statins for optimal efficacy and thus, has been associated with more adverse side effects. The objective of the current study was to test the hypothesis that a self assembling nanoemulsion (SANE) system which would reduce the particle size of typical Lovastatin preparations, and convert this hydrophobic entity to a stable water dispersion could consequently improve its efficacy, as it relates to cellular cholesterol accumulation and apo B (the major apoprotein of LDL) secretion, while lowering the doses needed to produce these results. A .. View More»
DOI:
10.4172/2157-7439.1000151